MedTrace Logo

Antiplatelet Therapies in Patients With Depression and Coronary Disease

NCT05821062 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2023-04-20

No results posted yet for this study

Summary

Depression after an acute coronary syndrome (ACS) but also at any time after CAD diagnosis, is highly associated with death, and it predicts mortality more than any other risk factor, comorbidity or follow-up events, suggesting that the standard medical therapy may not be sufficient to prevent the poor prognosis in these patients.

This study aims to assess whether depression might affect the response to dual antiplatelet therapy (DAPT) as recommended in coronary artery disease (CAD) patients.

Specific aims:

* to evaluate whether depression affects the antithrombotic response during Aspirin (ASA) plus clopidogrel (CLP) therapy in CAD patients.
* to assess the antithrombotic effects of ASA plus ticagrelor or prasugrel (TCG/PSG) therapy in CAD patients with depression by evaluating pro-thrombotic phenotype in CAD patients with and without depression during ASA+TCG/PSG.
* to assess whether there is or not the reactivation of pro-thrombotic profile after cessation of dual antiplatelet therapy in CAD patients with or without depression in single antiplatelet therapy after TCG/PSG cessation.

Conditions

Interventions

OTHER

standard Aspirin (ASA) + clopidogrel (CLP) therapy

ASA100mg + CLP 75mg daily

OTHER

standard Aspirin (ASA) + Ticagrelor (TCG) or Prasugrel (PSG) therapy

ASA 100 mg + TCG 90mg/b.i.d or PSG10mg daily

OTHER

standard ASA therapy

ASA 100 mg daily

Sponsors & Collaborators

  • IRCCS National Neurological Institute "C. Mondino" Foundation

    collaborator OTHER

  • Centro Cardiologico Monzino

    lead OTHER

Principal Investigators

  • Giancarlo Marenzi, MD · IRCCS Centro Cardiologico Monzino

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-14
Primary Completion
2024-02-29
Completion
2024-02-29

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05821062 on ClinicalTrials.gov